Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

1,633 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
First FDA approval of dual anti-HER2 regimen: pertuzumab in combination with trastuzumab and docetaxel for HER2-positive metastatic breast cancer.
Blumenthal GM, Scher NS, Cortazar P, Chattopadhyay S, Tang S, Song P, Liu Q, Ringgold K, Pilaro AM, Tilley A, King KE, Graham L, Rellahan BL, Weinberg WC, Chi B, Thomas C, Hughes P, Ibrahim A, Justice R, Pazdur R. Blumenthal GM, et al. Among authors: hughes p. Clin Cancer Res. 2013 Sep 15;19(18):4911-6. doi: 10.1158/1078-0432.CCR-13-1212. Epub 2013 Jun 25. Clin Cancer Res. 2013. PMID: 23801166
FDA approval: ado-trastuzumab emtansine for the treatment of patients with HER2-positive metastatic breast cancer.
Amiri-Kordestani L, Blumenthal GM, Xu QC, Zhang L, Tang SW, Ha L, Weinberg WC, Chi B, Candau-Chacon R, Hughes P, Russell AM, Miksinski SP, Chen XH, McGuinn WD, Palmby T, Schrieber SJ, Liu Q, Wang J, Song P, Mehrotra N, Skarupa L, Clouse K, Al-Hakim A, Sridhara R, Ibrahim A, Justice R, Pazdur R, Cortazar P. Amiri-Kordestani L, et al. Among authors: hughes p. Clin Cancer Res. 2014 Sep 1;20(17):4436-41. doi: 10.1158/1078-0432.CCR-14-0012. Epub 2014 May 30. Clin Cancer Res. 2014. PMID: 24879797 Clinical Trial.
Microbial Risk in Pharmaceutical Manufacturing and ICH Q9.
Guilfoyle DE, Friedman RL, Hughes PF, Hussong D, Rosenberg AS, Brorson K. Guilfoyle DE, et al. PDA J Pharm Sci Technol. 2013 Mar-Apr;67(2):79-80. doi: 10.5731/pdajpst.2013.00915. PDA J Pharm Sci Technol. 2013. PMID: 23569069 No abstract available.
State Differences in Children's Mental Health Care.
Graaf G, Hughes PM, Gigli KH, deJong NA, McGrath RE, Thomas KC. Graaf G, et al. Among authors: hughes pm. Acad Pediatr. 2024 Oct 1:S1876-2859(24)00504-7. doi: 10.1016/j.acap.2024.09.009. Online ahead of print. Acad Pediatr. 2024. PMID: 39362631
In-Person Healthcare Simulation: An Umbrella Review of the Literature.
Palaganas JC, Mosher C, Wawersik D, Eller S, Kirkpatrick AJ, Lazarovici M, Brown KM, Stapleton S, Hughes PG, Tarbet A, Morton A, Duff JP, Gross IT, Sanko J. Palaganas JC, et al. Among authors: hughes pg. Simul Healthc. 2024 Oct 1. doi: 10.1097/SIH.0000000000000822. Online ahead of print. Simul Healthc. 2024. PMID: 39353859
AMG 193, a Clinical Stage MTA-Cooperative PRMT5 Inhibitor, Drives Antitumor Activity Preclinically and in Patients With MTAP-Deleted Cancers.
Belmontes B, Slemmons KK, Su C, Liu S, Policheni AN, Moriguchi J, Tan H, Xie F, Aiello DA, Yang Y, Lazaro R, Aeffner F, Rees MG, Ronan MM, Roth JA, Vestergaard M, Cowland S, Andersson J, Sarvary I, Chen Q, Sharma P, Lopez P, Tamayo N, Pettus LH, Ghimire-Rijal S, Mukund S, Allen JR, DeVoss J, Coxon A, Rodon J, Ghiringhelli F, Penel N, Prenen H, Glad S, Chuang CH, Keyvanjah K, Townsley DM, Butler JR, Bourbeau MP, Caenepeel S, Hughes PE. Belmontes B, et al. Among authors: hughes pe. Cancer Discov. 2024 Sep 16. doi: 10.1158/2159-8290.CD-24-0887. Online ahead of print. Cancer Discov. 2024. PMID: 39282709
1,633 results